EGFR and neoplasm: MAPK signaling rebound is recognized as an essential resistance mechanism in BRAF-mutant tumor treatment (23), so we tested whether a MOGAT3 inhibitor combined with dual therapy would inhibit p-ERK rebound more profoundly than anti-BRAF/EGFR treatment.